{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Aeglea BioTherapeutics, Inc."},"Symbol":{"label":"Symbol","value":"AGLE"},"Address":{"label":"Address","value":"805 LAS CIMAS PARKWAY SUITE 100, AUSTIN, Texas, 78746, United States"},"Phone":{"label":"Phone","value":"+1 512 942-2935"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage."},"CompanyUrl":{"label":"Company Url","value":"https://www.aegleabio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Cortney Caudill","title":"Chief Operating Officer"},{"name":"Mark Bechter","title":"Vice President-Medical Affairs"},{"name":"Scott W. Rowlinson","title":"Vice President-Research"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}